Small infections can be fatal: Millions of people die each year from sepsis, an overreaction of the immune system. A new immune signaling molecule, designed by a research team from the Technical University of Munich (TUM), now provides the basis for potential new approaches in sepsis therapy. The numbers are alarming: According to estimates by the World Health Organization (WHO), around six million people die every year from sepsis. The disease, popularly called "blood poisoning", normally starts with a harmless infection.
25 January, 2019
Research also identified a rationally-defined consortium of human commensal bacteria (VE800) that robustly induces IFNy+ CD8+ T cells and enhances antitumor immunity . Vedanta’s clinical candidate VE800 is expected to enter clinical studies in 2019 in combination with Bristol-Myers Squibb’s checkpoint inhibitor OPDIVO® (nivolumab)
24 January, 2019
Two in five parents are exposed to negative messages about vaccines on social media and this rises to one in two among parents of under 5s. Across a range of vaccines including MMR, HPV, and Flu, fear of side effects was the most common reason for choosing not to vaccinate.
24 January, 2019
The topic of this month’s newsletter from Drug Discovery Today is “Targets”.
15 January, 2019
Alzheimer’s-affected brains are riddled with so-called amyloid plaques: protein aggregates consisting mainly of amyloid-ß. However, this amyloid-ß is a fragment produced from a precursor protein whose normal function has remained enigmatic for decades. A team of scientists at VIB and KU Leuven led by professors Joris de Wit and Bart De Strooper has now uncovered that this amyloid precursor protein modulates neuronal signal transmission through binding to a specific receptor. Modulating this receptor could potentially help treat Alzheimer’s or other brain diseases. The results are published in Science.
11 January, 2019
NICE has today (10 January) published draft guidance for public consultation which does not recommend erenumab (Aimovig, Novartis) for preventing migraine.
10 January, 2019
Data-driven analysis of innovation activities identifies five emerging trends and points to the need for greater cross-industry collaboration
09 January, 2019
Boehringer Ingelheim is to make the BET degrader compound MZ 1 available through its opnMe.com portal. The company actively supports open access in order to boost progress in biomedical and drug discovery research. MZ 1 (created at the University of Dundee) is the first external compound to be added to Boehringer Ingelheim’s’ opnMe.com portal.
09 January, 2019
Consumption of one egg every day seems to associate with a blood metabolite profile that is related to a lower risk of type 2 diabetes, a new study conducted in the University of Eastern Finland shows. The findings were published in Molecular Nutrition and Food Research.
08 January, 2019
Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage. This is the first test of its kind to investigate multiple cancer types.
07 January, 2019